BACKGROUND: This prospective study examines the effect of clozapine on factors determining glucose homeostasis. METHOD: The sample consisted of all patients meeting DSM-IV criteria for schizophrenia who commenced clozapine treatment within the South London and Maudsley hospitals during 1 year (2000-2001). Growth hormone (GH), insulin-like growth factor-1 (IGF-1), and IGF binding protein-1 (IGFBP-1) were measured in 19 patients (10 female; mean age = 31.1 years [SD = 5.8]; 9 black British/African, 10 white British) before and after a mean of 2.5 (SD = 0.9) months of clozapine treatment. RESULTS: Baseline IGFBP-1 was low. IGFBP-1, GH, and IGF-1 were not significantly changed by clozapine treatment. CONCLUSIONS: Clozapine does not alter GH, IGF-1, or IGFBP-1 within 3 months of commencing treatment, indicating that alteration in glucose tolerance associated with clozapine treatment involves other mechanisms yet to be elucidated. Baseline abnormalities in IGFBP-1 indicate a preexisting susceptibility to glucoregulatory dysfunction.
BACKGROUND: This prospective study examines the effect of clozapine on factors determining glucose homeostasis. METHOD: The sample consisted of all patients meeting DSM-IV criteria for schizophrenia who commenced clozapine treatment within the South London and Maudsley hospitals during 1 year (2000-2001). Growth hormone (GH), insulin-like growth factor-1 (IGF-1), and IGF binding protein-1 (IGFBP-1) were measured in 19 patients (10 female; mean age = 31.1 years [SD = 5.8]; 9 black British/African, 10 white British) before and after a mean of 2.5 (SD = 0.9) months of clozapine treatment. RESULTS: Baseline IGFBP-1 was low. IGFBP-1, GH, and IGF-1 were not significantly changed by clozapine treatment. CONCLUSIONS: Clozapine does not alter GH, IGF-1, or IGFBP-1 within 3 months of commencing treatment, indicating that alteration in glucose tolerance associated with clozapine treatment involves other mechanisms yet to be elucidated. Baseline abnormalities in IGFBP-1 indicate a preexisting susceptibility to glucoregulatory dysfunction.
Authors: Philip S Wang; Robert J Glynn; David A Ganz; Sebastian Schneeweiss; Raisa Levin; Jerry Avorn Journal: J Clin Psychopharmacol Date: 2002-06 Impact factor: 3.153
Authors: Michael J Sernyak; Douglas L Leslie; Renato D Alarcon; Miklos F Losonczy; Robert Rosenheck Journal: Am J Psychiatry Date: 2002-04 Impact factor: 18.112
Authors: John W Newcomer; Dan W Haupt; Robert Fucetola; Angela K Melson; Julie A Schweiger; Benjamin P Cooper; Gregg Selke Journal: Arch Gen Psychiatry Date: 2002-04
Authors: Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham Journal: Lancet Date: 2002-05-18 Impact factor: 79.321
Authors: P Gardner-Sood; J Lally; S Smith; Z Atakan; K Ismail; K E Greenwood; A Keen; C O'Brien; O Onagbesan; C Fung; E Papanastasiou; J Eberhard; J Eberherd; A Patel; R Ohlsen; D Stahl; A David; D Hopkins; R M Murray; F Gaughran Journal: Psychol Med Date: 2015-05-12 Impact factor: 7.723
Authors: Carlos Fernández-Pereira; Maria Aránzazu Penedo; Tania Rivera-Baltanas; Rafael Fernández-Martínez; Saida Ortolano; José Manuel Olivares; Roberto Carlos Agís-Balboa Journal: Int J Mol Sci Date: 2022-08-24 Impact factor: 6.208